New investigations into retatrutide, a dual activator for GLP-1 and GIP receptors, are demonstrating encouraging results in treating obesity and diabetes 2 disease. Preclinical evidence suggest a distinct mechanism https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/